Revelation Biosciences, Inc. (REVB) · Nov 5, 2026 · Earnings
Beat — GAAP EPS ($5.92) vs approximately ($6.16) consensus
Revelation Biosciences earnings narrowly beat estimates while the company advances its AKI trial setup and stretches cash into Q2 2027.
Revelation is a clinical-stage biotech building Gemini toward a planned Phase 2/3 acute-kidney-injury study, after agreeing with the FDA on a roughly 300-patient adaptive pathway; its 2026 work has focused on assembling the trial infrastructure rather than producing clinical data.
The quarter modestly cleared the earnings bar. Reported GAAP loss per share was $5.92 versus a published consensus of approximately $6.16, a narrow beat; there is no revenue to assess because Revelation remains pre-commercial. The lower per-share loss is also influenced by a much larger share base than last year, so it is not evidence of improving underlying economics.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net loss (Results of Operations) | $3.3M | $1.9M | |
| Loss per share (Results of Operations) | ($5.92) | ($49.51) | ($6.16) |
| Operating cash burn (Results of Operations) | $2.6M | $1.6M | |
| Cash balance (Balance Sheet) | $9.1M | $10.7M at Dec. 31, 2025 |
Operational progress is real but still preparatory. Selecting a global CRO moves GEM-AKI closer to execution, but it is a setup milestone rather than a study start, enrollment update, or efficacy readout. 〔0〕
Liquidity looks less immediately constrained, though financing risk remains. Management now says the $9.1 million cash balance should fund operations into the second quarter of 2027, while the June 2026 filing had warned that cash would not sustain operations for a year and raised substantial doubt about going concern. The caveat is that quarterly operating cash use rose to $2.6 million from $1.6 million, and the company still has no product revenue; the runway therefore depends on current spending assumptions holding. 〔1〕
The $94 billion market estimate adds narrative, not validation. It may support the commercial opportunity management is presenting, but this filing supplies no new human efficacy, safety, enrollment, or regulatory evidence for Gemini.
Bottom line: This is a small step forward: a narrow earnings beat, a CRO selected, and a stated cash runway into Q2 2027. The business story improves slightly, but the company remains an unproven, cash-burning biotech still waiting for the AKI study to begin and generate meaningful clinical evidence.
GEM-AKI study initiation update, targeted for Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!